A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors

Immunotherapy

Volumn 8, Issue 5, 2016, Pages 665-674

  Abdel Rahman, Omar ^a   Fouad, Mona ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

ipilimumab; nephritis; nivolumab; pembrolizumab

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNE CHECKPOINT INHIBITOR; IPILIMUMAB; IPILIMUMAB PLUS NIVOLUMAB; NIVOLUMAB; UNCLASSIFIED DRUG; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; HUMAN; IMMUNOTOXICITY; META ANALYSIS; MONOTHERAPY; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; ANIMAL; CARCINOMA, RENAL CELL; COMBINATION DRUG THERAPY; COMPLICATION; DRUG EFFECTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; IMMUNOLOGY; KIDNEY; PATHOLOGY; RISK;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, RENAL CELL; CTLA-4 ANTIGEN; DRUG THERAPY, COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; KIDNEY; PROGRAMMED CELL DEATH 1 RECEPTOR; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK;

EID: 84968911282     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt-2015-0020     Document Type: Review

References (40)

1. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10(9), 909-915 (2004).
2. Momtaz P, Postow MA. Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmgenomics Pers. Med. 7, 357 (2014).
3. Hodi FS, O'day SJ, Mcdermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
4. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26), 2517-2526 (2011).
5. Hamid O, Robert C, Daud A et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369(2), 134-144 (2013).
6. Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372(26), 2521-2532 (2015).
7. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372(21), 2018-2028 (2015).
8. Berger R, Rotem-Yehudar R, Slama G et al. Phase I safety and pharmacokinetic study of ct-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 14(10), 3044-3051 (2008).
9. Armand P, Nagler A, Weller EA et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international Phase II trial. J. Clin. Oncol. 31(33), 4199-4206 (2013).
10. Spira A, Park K, Mazieres J, Vansteenkiste J, Rittmeyer A, Ballinger M. Efficacy, safety and predictive biomarker results from a randomized phase II study comparing atezolizumab (MPDL3280A) vs docetaxel in 2L/3L NSCLC (POPLAR). J. Clin. Oncol. 33 (2015).
11. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-l1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455-2465 (2012).
12. Abdel-Rahman O, Elhalawani H, Fouad M. Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: A meta-analysis. Future Oncol. 11(17), 2471-2484 (2015).
13. Abdel-Rahman O, Elhalawani H, Fouad M. Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: A meta-analysis. Expert Opin. Drug Saf. 14(10), 1507-1518 (2015).
14. Abdel-Rahman O, El Halawani H, Fouad M. Risk of endocrine complications in cancer patients treated with immune check point inhibitors; a meta-analysis. Future Oncol. (2015).
15. Abdel-Rahman O, ElHalawani H. , Fouad M. Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors; a meta-analysis. Immunotherapy 7(11), 1213-1227 (2015).
16. Westin JR, Chu F, Zhang M et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: A single group, open-label, Phase 2 trial. Lancet Oncol. 15(1), 69-77 (2014).
17. Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J. Clin. Endocrinol. Metab. 98(4), 1361-1375 (2013).
18. Torino F, Barnabei A, Paragliola RM, Marchetti P, Salvatori R, Corsello SM. Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. Eur. J. Endocrinol. 169(6), R153-R164 (2013).
19. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. Ann. Intern. Med. 151(4), 264-269 (2009).
20. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control. Clin. Trials 17(1), 1-12 (1996).
21. Caldwell DM, Ades A, Higgins J. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. Br. Med. J. 331(7521), 897 (2005).
22. Lu G, Ades A. Combination of direct and indirect evidence in mixed treatment comparisons. Stat. Med. 23(20), 3105-3124 (2004).
23. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous cell non-small-cell lung cancer. N. Engl. J. Med. (2015).
24. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without braf mutation. N. Engl. J. Med. 372(4), 320-330 (2015).
25. Weber JS, D'angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (checkmate 037): A randomised, controlled, open-label, Phase 3 trial. Lancet Oncol. 16(4), 375-384 (2015).
26. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373(17), 1627-1639 (2015).
27. Ribas A, Puzanov I, Dummer R et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (keynote-002): A randomised, controlled, Phase 2 trial. Lancet Oncol. 16(8 ), 908-918 (2015).
28. Postow MA, Chesney J, Pavlick AC et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372(21), 2006-2017 (2015).
29. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373(1), 23-34 (2015).
30. Abdel-Rahman O. Immune checkpoints aberrations and gastric cancer; assessment of prognostic value and evaluation of therapeutic potentials. Crit. Rev. Oncol. Hematol. (2015).
31. Intlekofer AM, Thompson CB. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J. Leukoc. Biol. 94(1), 25-39 (2013).
32. Alegre M-L, Noel PJ, Eisfelder BJ et al. Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J. Immunol. 157(11), 4762-4770 (1996).
33. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012).
34. Izzedine H, Gueutin V, Gharbi C et al. Kidney injuries related to ipilimumab. Invest. New Drugs 32(4), 769-773 (2014).
35. Fadel F, Karoui KE, Knebelmann B. Anti-ctla4 antibody-induced lupus nephritis. N. Engl. J. Med. 361(2), 211-212 (2009).
36. Abdel-Rahman O, Elhalawani H. Proteinuria in patients with solid tumors treated with ramucirumab: A systematic review and meta-analysis. Chemotherapy 60(5-6), 325-333 (2014).
37. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 30(21), 2691-2697 (2012).
38. Thajudeen B, Madhrira M, Bracamonte E, Cranmer LD. Ipilimumab granulomatous interstitial nephritis. Am. J. Ther. 22(3), e84-e87 (2015).
39. Motzer RJ, Escudier B, Mcdermott DF et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373(19), 1803-1813 (2015).
40. Bronstein Y, Ng CS, Hwu P, Hwu W-J. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am. J. Roentgenol. 197(6), W992-W1000 (2011).